

Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (Withdrawn): A lactic composition comprising a mixture of bacterial strain, *Lactobacillus acidophilus* and *Lactobacillus casei*, and a whole broth of said mixture, characterized in that the lactic composition is for the prevention or the treatment of angiogenesis dependant disorders.

Claim 2 (Withdrawn): A lactic composition according to claim 1, characterized in that the at least one *Lactobacillus acidophilus* strain is strain I-1492 deposited at the CNCM.

Claim 3 (Withdrawn): A lactic composition according to claim 2, characterized in that it comprises at least 500 millions per gram of a population of living and active microorganisms of the *Lactobacillus acidophilus* strains after 90 days under refrigeration, where at least 380 millions per gram are micro-organisms of the *Lactobacillus acidophilus* CNCM I-1492 strain.

Claim 4 (Withdrawn): A lactic composition according to claim 3, characterized in that it further comprises fermented milk proteins or fermented soy proteins.

Claim 5 (Withdrawn): A supernatant obtained from the lactic composition as defined in any one of claims 1 to 4, characterized in that said supernatant exhibits antiangiogenic properties.

Claim 6 (Withdrawn): The supernatant according to claim 5, characterized in that said supernatant is concentrated.

Claim 7 (Withdrawn): The supernatant according to claims 5 or 6, characterized in that said supernatant is 10X concentrated.

Claim 8 (Withdrawn): The supernatant according to anyone of claims 5 to 7, characterized in that it comprises molecules of a size larger than 5000 kDa.

Claim 9 (Withdrawn): Use of the supernatant as defined in any one of claims 5 to 8, as an antiangiogenic agent.

Claim 10 (Withdrawn): Use of the supernatant as defined in any one of claims 5 to 8, in the prevention or the treatment of an angiogenesis dependant disorder in a mammal.

Claim 11 (Withdrawn): Use according to claim 10, wherein said mammal is a human being.

Claim 12 (Withdrawn): Use according to claim 10, wherein said disorder is selected from the group consisting of retinopathy, infantile haemangioma, rheumatoid arthritis, psoriasis, duodenal ulcers, post-angioplasty restenosis and tumor growth.

Claim 13 (Withdrawn): Use of a supernatant according to claim 12, wherein said disorder is tumor growth.

Claims 14-18 (Canceled)

Claim 19 (Currently Amended): A method for prevention or treatment of an angiogenesis dependent disorder, the method comprising administering to a mammal an effective amount of a lactic composition comprising a mixture of bacterial strains [[,]] selected from the group consisting of *Lactobacillus acidophilus* and *Lactobacillus casei*, and a whole broth of said mixture, wherein at least one *Lactobacillus acidophilus* strain is I-1492 deposited at the CNCM

and wherein the angiogenesis dependent disorder is selected from the group consisting of retinopathy, infantile haemangioma, rheumatoid arthritis, psoriasis, and post-angioplasty restenosis.

Claim 20 (Previously presented): The method according to claim 19, wherein said mammal is a human being.

Claims 21 and 22 (Canceled)

Claim 23 (Previously presented): The method according to claim 19 or 20, wherein said administration is oral administration.

Claim 24 (Canceled)

Claim 25 (Previously presented): The method of claim 19, wherein the lactic composition further comprises fermented milk proteins or fermented soy proteins.

Claim 26 (New): A method for inhibiting angiogenesis, the method comprising administering to a mammal an effective amount of a lactic composition comprising a mixture of bacterial strains selected from the group consisting of *Lactobacillus acidophilus* and *Lactobacillus casei*, and a whole broth of said mixture, wherein at least one *Lactobacillus acidophilus* strain is I-1492 deposited at the CNCM.